论文部分内容阅读
目的:探讨和研究贝那普利与来氟米特治疗慢性肾小球肾炎患者的临床疗效和治疗前后生化指标的变化情况。方法:选取2010.1~2012.12之间收治的100例慢性肾小球肾炎患者作为研究对象,根据患者入院编号进行随机分组,对照组50例给予小剂量泼尼松联合贝那普利进行治疗,观察组则给予小剂量泼尼松联合来氟米特进行治疗,两组患者治疗时间均为3个月,治疗结束后统计疗效。结果:从两组患者的疗效来看,观察组患者的总有效率为98.0%,对照组的总有效率为82.0%,观察组显著优于对照组,差异具有统计学意义(P<0.05)。结论:小剂量泼尼松联合来氟米特治疗慢性肾小球肾炎的疗效更加确切,相较于贝那普利而言能够更好的提高患者的肾功能,降低蛋白尿,安全性也较好,值得在临床上推广和应用。
Objective: To investigate and study benazepril and leflunomide in patients with chronic glomerulonephritis clinical efficacy and biochemical indicators before and after treatment changes. Methods: A total of 100 patients with chronic glomerulonephritis treated between 2010.1 and 2012.12 were enrolled in this study. Patients were randomized according to hospital admission numbers. 50 patients in the control group were treated with low-dose prednisone and benazepril. The observation group Then given a small dose of prednisone combined with leflunomide treatment, two groups of patients were treated for 3 months, after the end of treatment statistics. Results: The total effective rate was 98.0% in the observation group and 82.0% in the control group. The observation group was significantly better than the control group, the difference was statistically significant (P <0.05) . CONCLUSIONS: The efficacy of low-dose prednisone combined with leflunomide in the treatment of chronic glomerulonephritis is more precise, which is better than benazepril in improving renal function and reducing proteinuria Well, it is worth to promote and apply in clinic.